Neurotrophic Keratopathy clinical trials at University of California Health

• Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy

  open to eligible people ages 18 years and up

  The objective of this study is to evaluate the safety and effectiveness of OC-01 (varenicline) nasal spray as compared to placebo nasal spray for complete resolution of corneal staining (0 mm lesion and no residual staining) in subjects with Stage 1 (corneal epithelial hyperplasia/punctate keratopathy) neurotrophic keratopathy (NK) in one or both eyes.

  at UCLA

Last updated: October 7, 2021